London, UK – 3 March, 2026 – Quell Therapeutics Ltd (“Quell”), today announced that it has initiated a Phase 1/2 basket clinical study evaluating ...
Quell Therapeutics has begun its chill phase 1/2 clinical trial evaluating QEL‑005, an autologous CAR‑Treg therapy designed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results